Profile data is unavailable for this security.
About the company
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.
- Revenue in USD (TTM)0.00
- Net income in USD-51.32m
- Incorporated2018
- Employees9.00
- LocationCytodyn Inc1111 Main St Ste 660VANCOUVER 98660-2970United StatesUSA
- Phone+1 (360) 980-8524
- Fax+1 (302) 655-5049
- Websitehttps://www.cytodyn.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc | 0.00 | -19.90m | 185.95m | 18.00 | -- | 3.48 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Caribou Biosciences Inc | 33.11m | -123.44m | 189.76m | 158.00 | -- | 0.6112 | -- | 5.73 | -1.39 | -1.39 | 0.3763 | 3.44 | 0.0917 | -- | 15.61 | 209,576.00 | -34.17 | -- | -37.56 | -- | -- | -- | -372.78 | -- | -- | -1,231.11 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Gossamer Bio Inc | 95.84m | -80.85m | 203.31m | 135.00 | -- | 2.49 | -- | 2.12 | -0.3996 | -0.3996 | 0.434 | 0.3604 | 0.3453 | -- | -- | 709,940.80 | -29.13 | -57.43 | -34.41 | -64.38 | -- | -- | -84.36 | -- | -- | -7.07 | 0.7073 | -- | -- | -- | 21.61 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.32m | 204.10m | 9.00 | -- | -- | -- | -- | -0.0527 | -0.0527 | 0.00 | -0.1103 | 0.00 | -- | -- | 0.00 | -444.45 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | -2.76 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -89.98m | 204.68m | 136.00 | -- | 1.01 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Vaxart Inc | 13.93m | -75.66m | 210.27m | 109.00 | -- | 2.63 | -- | 15.10 | -0.4707 | -0.4707 | 0.0861 | 0.3518 | 0.1178 | -- | 5.80 | 127,779.80 | -64.01 | -49.60 | -73.18 | -54.86 | -- | -- | -543.21 | -1,398.00 | -- | -226.73 | 0.0507 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| MacroGenics Inc | 41.02m | -136.37m | 211.06m | 339.00 | -- | 3.65 | -- | 5.15 | -2.19 | -2.19 | 0.6583 | 0.9218 | 0.1619 | 6.62 | 6.51 | 120,997.00 | -53.82 | -37.76 | -67.56 | -45.53 | 79.37 | -- | -332.47 | -133.96 | 2.69 | -172.62 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Pyxis Oncology Inc | 16.15m | -59.20m | 212.78m | 51.00 | -- | 1.25 | -- | 13.18 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 217.78m | 76.00 | -- | 0.7935 | -- | 2.67 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Codexis Inc | 60.89m | -76.36m | 224.13m | 174.00 | -- | 3.65 | -- | 3.68 | -1.09 | -1.09 | 0.8723 | 0.8665 | 0.3595 | 6.27 | 3.58 | 349,942.50 | -45.08 | -17.13 | -56.05 | -20.23 | 77.95 | 77.29 | -125.41 | -37.04 | 2.92 | -- | 0.3158 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| XBiotech Inc | 0.00 | -35.01m | 225.12m | 94.00 | -- | 1.14 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Candel Therapeutics Inc | 0.00 | -49.99m | 225.40m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Diversified Trust Co.as of 30 Jun 2024 | 45.79k | 0.00% |
| Virtue Capital Management LLCas of 30 Jun 2024 | 45.00k | 0.00% |
| Moloney Securities Asset Management LLCas of 30 Jun 2024 | 28.03k | 0.00% |
| Williams Jones Wealth Management LLCas of 30 Jun 2024 | 25.00k | 0.00% |
| S.A. Mason LLCas of 30 Jun 2024 | 19.00k | 0.00% |
| Horizon Financial Services LLCas of 30 Jun 2024 | 18.20k | 0.00% |
| FineMark National Bank & Trust (Invt Mgmt)as of 30 Jun 2024 | 15.00k | 0.00% |
| Willis Investment Counsel, Inc.as of 30 Jun 2024 | 13.04k | 0.00% |
| Ancora Family Wealth Advisors LLCas of 30 Jun 2024 | 9.49k | 0.00% |
| Able Wealth Management LLCas of 31 Dec 2023 | 5.91k | 0.00% |
